What Is NAD+ and Why Does It Matter for Healthy Aging?

The NAD+ Conundrum: Why This Molecule Declines and What Research Suggests

By the Lumnira Research Desk | Updated June 2026

Introduction

Nicotinamide adenine dinucleotide, or NAD+, is a coenzyme found in every living cell. It participates in hundreds of metabolic reactions and is essential for converting food into cellular energy. Without NAD+, your cells cannot generate ATP, repair damaged DNA, or maintain mitochondrial function.

The conundrum is this: NAD+ levels decline significantly with age. By middle age, your NAD+ levels may be roughly half of what they were in your twenties. This decline is associated with natural changes in metabolic function, mitochondrial efficiency, and cellular repair mechanisms.

Researchers have spent the past decade investigating why NAD+ declines and whether the decline can be modulated. This article examines the key studies that shaped the current understanding of NAD+ biology, the enzymatic pathways involved, and the early human data on NMN (nicotinamide mononucleotide) supplementation.

What Is NAD+ and Why Does It Matter?

NAD+ exists in two forms: NAD+ (oxidized) and NADH (reduced). The ratio between these forms reflects the cell's redox state and energy status. When you eat food, NAD+ accepts electrons from metabolic substrates, becoming NADH. NADH then donates those electrons to the mitochondrial electron transport chain, driving ATP production.

Beyond energy metabolism, NAD+ serves as a required substrate for several families of enzymes. Sirtuins, a family of seven protein deacetylases, use NAD+ to remove acetyl groups from proteins, regulating gene expression, DNA repair, and metabolic homeostasis. PARPs (poly ADP-ribose polymerases) consume NAD+ during DNA damage repair. CD38, an enzyme that increases with age, breaks down NAD+ as part of its normal catalytic cycle.

The key insight is that NAD+ is not just a passive coenzyme. It is a signaling molecule that connects metabolic status to cellular defense and repair. When NAD+ is abundant, sirtuins are active, DNA repair proceeds efficiently, and mitochondrial function is maintained. When NAD+ is scarce, these processes slow down.

The Age-Related Decline: What Gomes 2013 Revealed

A landmark study by Gomes and colleagues, published in 2013 in Cell, provided a detailed mechanistic explanation for natural NAD+ decline. The researchers demonstrated that mitochondrial dysfunction, which accumulates with aging, leads to increased levels of acetylated proteins. These acetylated proteins, in turn, require sirtuin activity to be deacetylated, consuming NAD+ in the process.

The study showed that restoring NAD+ levels in aged mice, through supplementation with NMN, reversed mitochondrial dysfunction. The treated mice exhibited improved mitochondrial function markers and metabolic profiles. Gomes 2013 established a direct link between NAD+ decline, mitochondrial aging, and the potential for NAD+ precursor supplementation to address these changes.

This was not a finding about a single organ. The mitochondrial-NAD+ axis operates in muscle, liver, brain, and other tissues. The implications for whole-body aging were significant, and the paper became one of the most cited in the NAD+ literature.

NAD+ Biosynthesis: The Salvage Pathway

The body maintains NAD+ through three primary pathways: the de novo pathway (from tryptophan), the Preiss-Handler pathway (from niacin), and the salvage pathway (from nicotinamide). The salvage pathway is the dominant route for NAD+ maintenance in most tissues.

In the salvage pathway, nicotinamide mononucleotide (NMN) is an intermediate compound. NMN is synthesized from nicotinamide (a form of vitamin B3) by the enzyme NAMPT (nicotinamide phosphoribosyltransferase). NMN is then converted to NAD+ by NMNAT (nicotinamide mononucleotide adenylyltransferase) enzymes located in the nucleus, cytoplasm, and mitochondria.

The rationale for NMN supplementation is straightforward: if the salvage pathway becomes rate-limited with age, providing exogenous NMN may bypass the bottleneck and restore NAD+ synthesis. This is the hypothesis that Mills and colleagues tested in their 2016 study, published in Cell Metabolism.

Mills 2016 administered NMN to aged mice and examined multiple markers of health and metabolic function. The results showed that long-term NMN supplementation was associated with improved insulin sensitivity, enhanced mitochondrial function, and changes in gene expression patterns consistent with younger metabolic profiles. The treated mice did not show adverse effects, suggesting a favorable safety profile at the doses studied.

What made the Mills study stand out was its duration. While many supplementation studies last weeks, Mills administered NMN for over a year in mouse terms, covering a substantial portion of the animal's lifespan. The sustained benefits without toxicity provided confidence that NMN could be studied in longer-term human trials.

The salvage pathway is not the only route to NAD+. The de novo pathway begins with the amino acid tryptophan and proceeds through several enzymatic steps to produce NAD+. The Preiss-Handler pathway converts niacin (nicotinic acid) to NAD+ through a different set of intermediates. However, the salvage pathway is quantitatively dominant in most human tissues, which is why NMN and its close relative NR (nicotinamide riboside) have attracted the most research attention as NAD+ precursors.

CD38: The Enzyme That Drains Your NAD+ Reserves

Understanding why NAD+ declines requires understanding CD38. Camacho-Pereira and colleagues published a study in 2016 in Cell Metabolism that identified CD38 as a primary driver of natural NAD+ decline.

CD38 is a transmembrane glycoprotein with NAD+ hydrolase activity. It breaks down NAD+ and NMN, consuming them in the process. The Camacho-Pereira study demonstrated that CD38 expression and activity increase significantly with age in multiple tissues. This increase was associated with reduced NAD+ levels and impaired metabolic function.

The study had a striking finding: young CD38-knockout mice (mice genetically engineered to lack CD38) were protected from natural NAD+ decline. Their NAD+ levels remained higher than wild-type mice as they aged. This provided strong evidence that CD38 activity, not simply reduced NAD+ production, is a major contributor to the natural NAD+ drop.

Human Trials: NMN and NAD+ Metabolism

The transition from animal models to human trials is where NAD+ research currently stands. Yoshino and colleagues published a randomized, double-blind, placebo-controlled trial in 2021 in Science examining the effects of NMN supplementation in postmenopausal women with prediabetes.

Participants received 250 mg of NMN daily for 10 weeks. The study measured multiple metabolic endpoints, including insulin sensitivity, body composition, and markers of NAD+ metabolism. The NMN group demonstrated improved muscle insulin sensitivity compared to placebo. The researchers also observed changes in expression of genes involved in muscle remodeling and NAD+ biosynthesis.

Yoshino 2021 was significant because it was one of the first rigorous human trials to demonstrate a metabolic benefit of NMN supplementation. The study was well-designed, used a clinically relevant population, and measured objective endpoints. However, the sample size was modest, and the duration was relatively short. Larger, longer-term human studies are needed to confirm these findings and investigate broader health outcomes.

The connection between NAD+ and sirtuins deserves further attention. Sirtuins are sometimes called longevity genes because of their role in regulating cellular stress responses and metabolic efficiency. SIRT1, the most studied sirtuin, modulates inflammation, circadian rhythm, and fat metabolism. SIRT3, located in mitochondria, regulates oxidative stress and energy production. All seven sirtuins require NAD+ to function. When NAD+ levels fall, sirtuin activity declines in parallel. This creates a feedback loop: lower NAD+ means less sirtuin activity, which means less efficient mitochondrial function, which further depletes NAD+.

The Yoshino trial also examined gene expression patterns in muscle biopsies. The researchers found that NMN supplementation was associated with upregulation of genes involved in NAD+ biosynthesis and mitochondrial function. This suggests that exogenous NMN does not simply add to the existing NAD+ pool but may also stimulate the body's own NAD+ production machinery.

The NAD+ story is one of the most active areas of aging research. The preclinical evidence is robust. The human data is promising but early. What is clear is that NAD+ is not a passive bystander in the aging process. It is a central node in the metabolic network that supports cellular health, and its change over time is both measurable and, potentially, modifiable.

As research continues, the question shifts from whether NAD+ decline matters to how best to support NAD+ metabolism across the lifespan. The available evidence suggests that NMN supplementation represents one approach under active scientific investigation.

References

FDA Disclaimer: These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.